H L Rieder
Overview
Explore the profile of H L Rieder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
2768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rieder H, Declercq E, Rigouts L, Piubello A, Billo N, Ba F, et al.
Int J Tuberc Lung Dis
. 2024 Jan;
28(1):68-69.
PMID: 38178291
No abstract available.
2.
Gigi R, Rieder H, Padayatchi N
S Afr Med J
. 2020 Sep;
110(9):846-849.
PMID: 32880265
An HIV-positive mother infected her daughter with extensively drug-resistant Mycobacterium tuberculosis. Despite adhering to the then current guidelines for prevention, the infant was diagnosed with extensively drug-resistant pulmonary tuberculosis at...
3.
Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, Aung K, et al.
Int J Tuberc Lung Dis
. 2019 Oct;
23(9):965-971.
PMID: 31615602
Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon. To estimate the effect of either a gatifloxacin...
4.
Schwoebel V, Chiang C, Trebucq A, Piubello A, Ait-Khaled N, Koura K, et al.
Int J Tuberc Lung Dis
. 2019 May;
23(5):619-624.
PMID: 31097072
<sec id="st1"> <title>OBJECTIVE</title> To assess whether the revised 2013 World Health Organization (WHO) definitions for multidrug-resistant tuberculosis (MDR-TB) treatment outcomes apply to shorter treatment regimens in low- and middle-income countries...
5.
Van Deun A, Tahseen S, Affolabi D, Hossain M, Joloba M, Angra P, et al.
Int J Tuberc Lung Dis
. 2018 Dec;
23(1):12-18.
PMID: 30567624
A balanced perspective is advocated for the assessment and application of the most recent and the oldest diagnostic methods for pulmonary tuberculosis (TB)-the molecular Xpert MTB/RIF assay and microscopy for...
6.
Olaru I, Albert H, Zallet J, Werner U, Ahmed N, Rieder H, et al.
Int J Tuberc Lung Dis
. 2018 Feb;
22(3):309-320.
PMID: 29471910
Background: The effect of quality improvement measures on the performance of diagnostic tuberculosis (TB) laboratories in low- and lower-middle-income countries is not known, and is the subject of this review....
7.
Van Deun A, Decroo T, Piubello A, de Jong B, Lynen L, Rieder H
Int J Tuberc Lung Dis
. 2018 Feb;
22(3):239-245.
PMID: 29471899
Current World Health Organization guidelines for the formulation of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological activity of anti-tuberculosis drugs. Here, we draw lessons...
8.
Trebucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al.
Int J Tuberc Lung Dis
. 2017 Nov;
22(1):17-25.
PMID: 29149917
Setting: Nine countries in West and Central Africa. Objective: To assess outcomes and adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB) among patients never previously...
9.
Trebucq A, Harries A, Rieder H
Int J Tuberc Lung Dis
. 2017 Oct;
16(5):703-704.
PMID: 29070251
No abstract available.
10.
Chiang C, Van Deun A, Rieder H
Int J Tuberc Lung Dis
. 2016 Aug;
20(9):1143-7.
PMID: 27510237
The 9-month regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) piloted in Bangladesh and used, with modifications, in Cameroon and Niger, has achieved treatment success in a very large proportion...